PLAUR and cancer: reported reduced resistance to cisplatin, docetaxel, DOX, and 5-FU in drug-resistant cancer cell lines following the application of CRISPR/Cas9 to knock out urokinase plasminogen activator receptor (uPAR), which is overexpressed in several cancers (456).